Episode 42

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.

Next Episode All Episodes Previous Episode

About the Podcast

Show artwork for Breast Cancer Update
Breast Cancer Update
This series bridges the gap between research and patient care by providing on-going access to the perspectives and opinions of national and international breast cancer research leaders.

Listen for free